Lung Cancer in the Elderly Patient

Lee‐Chiong, Teofilo; Matthay, Richard A.

doi:10.1016/s0272-5231(21)00909-6

Cited by 41 publications

(2 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some cardiovascular, pulmonary, and other medical-related comorbidities may make patients ineligible for surgical treatment, 2,3 and a large proportion of older adults with NSCLC could have such comorbidities. 4 For patients with medically inoperable stage I NSCLC, stereotactic body radiation therapy (SBRT) has been considered as the standard of care. SBRT has been shown to be particularly effective in eradicating primary and metastatic tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Computed Tomography-Guided Percutaneous Radiofrequency Ablation in Older Adults With Early-Stage Peripheral Lung Cancer: A Retrospective Cohort Study

et al. 2022

Cancer Control

View full text Add to dashboard Cite

Objectives To evaluate the feasibility, safety, and efficacy of computed tomography(CT)-guided percutaneous radiofrequency ablation (RFA) in medically inoperable older adults with clinical stage I non-small cell lung cancer (NSCLC). Patients and Methods We retrospectively reviewed the records of medically inoperable older adults (≥70 years) with clinical stage I NSCLC who underwent percutaneous multi-tined electrode RFA at our institution between January 2014 and December 2018. We analyzed the patients’ characteristics, therapy response, survival, as well as the procedure-related complications. Results Eighteen patients (10 men and 8 women) with a mean age of 75.9 (71−85) years were treated in during the study period. The median tumor size was 25 mm (range, 19−43 mm); 10 and 8 cases involved stage T1 and T2a disease, respectively. The median follow-up duration was 25 (11–45) months. RFA was technically successful for all 18 lesions, with no treatment-related mortality. The disease control rate was 83.3% (15/18 lesions). There were 6 cases of pneumothorax: one symptomatic case requiring thoracic drainage, and five requiring no treatment. Minor complications, including pulmonary infection, chest pain, fever, and cough, were treated within 4 days (range, 1−4 days). The progression-free survival rates were 83.3%, 64.9%, and 51.9% 1, 2, and 3 years, respectively. The corresponding overall survival rates were 92.2%, 81.5%, and 54.3%, respectively. Conclusions CT-guided percutaneous RFA is safe and effective in medically inoperable patients with stage I NSCLC and could be an alternative therapeutic strategy, particularly in older adults with early-stage peripheral lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%